Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer

Oncology Letters
Jelena MaksimenkoEdvins Miklasevics

Abstract

Triple-negative breast cancer (TNBC) is proposed to be an immunohistochemical surrogate of the basal-like breast cancer subtype. In spite of the relative chemosensitivity of this cancer subtype, it is characterized by aggressive clinical behavior; therefore, a further subclassification of TNBC is required to develop new targeted treatment. In previous studies, a strong correlation between BRCA1 mutation-associated tumors and TNBC has been identified. The aim of the present study was to investigate the prognostic significance of carrying two germline BRCA1 founder mutations (4153delA and 5382insC) in patients with TNBC in the Latvian population. A total of 78 consecutive BRCA1 mutation-negative and 38 BRCA1 mutation-positive invasive TNBC patients in stage I-IV with no history of ovarian or other primary advanced cancers, who had undergone definitive surgery and genetic testing between 2005 and 2011, were deemed eligible for study. Relapse rates and breast cancer-specific survival (BCS) outcomes were compared between mutation carriers and non-carriers. Univariate and multivariate analyses Cox proportional-hazards models were used to compute independent predictors of survival outcomes. No statistically significant differences wer...Continue Reading

References

Jan 3, 2001·Proceedings of the National Academy of Sciences of the United States of America·C BegerF Wong-Staal
Oct 25, 2003·Science·Mary-Claire KingUNKNOWN New York Breast Cancer Study Group
Nov 1, 2005·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sandy AzoulayAnne Vincent-Salomon
Feb 14, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B T HennessyV Valero
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
May 2, 2007·International Journal of Cancer. Journal International Du Cancer·Pal MollerC Michael Steel
Jul 13, 2007·The New England Journal of Medicine·Gad RennertSteven A Narod
Jan 4, 2008·Histopathology·J S Reis-Filho, A N J Tutt
Jul 24, 2008·Breast Cancer Research and Treatment·T ByrskiS A Narod
Jul 29, 2008·The Breast Journal·Henry G Kaplan, Judith A Malmgren
Sep 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deann P AtchleyBanu K Arun
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emad A RakhaIan O Ellis
Oct 1, 2009·Breast Cancer Research and Treatment·L BordeleauP Goodwin
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel P SilverJudy E Garber
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Jan 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ana M Gonzalez-AnguloFunda Meric-Bernstam
Feb 10, 2011·The Oncologist·Charles M Perou
Aug 11, 2011·Breast Cancer Research and Treatment·Soley BayraktarBanu K Arun
Oct 29, 2011·BMC Medical Genetics·Grigorijs PlakhinsJanis Gardovskis
Jan 26, 2012·JAMA : the Journal of the American Medical Association·Kelly L BoltonUNKNOWN Cancer Genome Atlas Research Network

❮ Previous
Next ❯

Citations

May 3, 2018·Hereditary Cancer in Clinical Practice·Nikolai Havn SætherJanis Gardovskis
Dec 7, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C WangY Xie
Jan 27, 2016·BMC Systems Biology·Julia L FleckChristos G Cassandras
Oct 25, 2016·BMC Women's Health·Touria DerkaouiMohcine Bennani Mechita
Mar 24, 2016·Journal of Cancer Research and Clinical Oncology·Gilda SchmidtErich-Franz Solomayer
Oct 24, 2018·Breast Cancer Research and Treatment·Jai Min RyuUNKNOWN Korean Hereditary Breast Cancer Study Group
Apr 24, 2020·Journal of Oncology·Katarzyna PogodaZbigniew Nowecki
Feb 24, 2015·Hereditary Cancer in Clinical Practice·Dagnija KalnieteEdvīns Miklaševičs

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
prophylactic oophorectomy

Software Mentioned

SPSS

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Youlia M KirovaInstitut Curie Breast Cancer Study Group
Journal of the National Cancer Institute
Laufey TryggvadóttirHrafn Tulinius
© 2021 Meta ULC. All rights reserved